The Memorial Sloan Kettering Cancer Center SPORE in Lymphoma seeks to improve the cure rate of patients with diffuse large B cell lymphoma (DLBCL) — one of the most common forms of the disease — through a collaboration between MSK, Weill Cornell Medical College, and the Herbert Irving Comprehensive Cancer Center of Columbia University.
The SPORE will enable the Lymphoma Service to develop treatments that are more effective and safer based on recent advances in our knowledge of tumor biology, including newly identified genetic and biologic alterations in the cancer cells.
The overall approach for this Lymphoma SPORE is to transform clinical practice by introducing, developing, and applying new concepts, methods, and technologies to address several DLBCL subgroups with a clear unmet medical need. Our overall broad aims are:
Specific Aim 1. To develop novel treatments for DLBCL based on targeting specific genetic and molecular alterations that promote the cancer.
Specific Aim 2. To identify potential biomarkers showing how well new treatments are working using tissue specimens from patients enrolled on four clinical trials developed in the SPORE.
The principal investigator for the MSK SPORE in Lymphoma is Andrew D. Zelenetz, MD, PhD